1155 related articles for article (PubMed ID: 15797470)
1. Horse cytokine/IgG fusion proteins--mammalian expression of biologically active cytokines and a system to verify antibody specificity to equine cytokines.
Wagner B; Robeson J; McCracken M; Wattrang E; Antczak DF
Vet Immunol Immunopathol; 2005 May; 105(1-2):1-14. PubMed ID: 15797470
[TBL] [Abstract][Full Text] [Related]
2. [Development of IgHV family specific nucleic acid vaccine against lymphoma by construction of fusion gene of immunoglobulin heavy chain variable region and cytokine].
Liu H; Zhu P; Lin NJ; Zhang Y; Bu DF; Wang YJ; Wang YQ; Yang Y
Zhonghua Yi Xue Za Zhi; 2004 Jan; 84(1):48-53. PubMed ID: 14990159
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies to equine interferon-alpha (IFN-alpha): new tools to neutralize IFN-activity and to detect secreted IFN-alpha.
Wagner B; Hillegas JM; Flaminio MJ; Wattrang E
Vet Immunol Immunopathol; 2008 Oct; 125(3-4):315-25. PubMed ID: 18586327
[TBL] [Abstract][Full Text] [Related]
4. Bi-functional cytokine fusion proteins for gene therapy and antibody-targeted treatment of cancer.
Gillies SD; Lan Y; Brunkhorst B; Wong WK; Li Y; Lo KM
Cancer Immunol Immunother; 2002 Oct; 51(8):449-60. PubMed ID: 12202906
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibodies to equine CD23 identify the low-affinity receptor for IgE on subpopulations of IgM+ and IgG1+ B-cells in horses.
Wagner B; Hillegas JM; Babasyan S
Vet Immunol Immunopathol; 2012 Apr; 146(2):125-34. PubMed ID: 22405681
[TBL] [Abstract][Full Text] [Related]
6. Generation and characterization of a high-affinity chimaeric antibody against hepatitis B surface antigen.
Bose B; Khanna N; Acharya SK; Sinha S
Biotechnol Appl Biochem; 2006 Feb; 43(Pt 2):93-101. PubMed ID: 16253117
[TBL] [Abstract][Full Text] [Related]
7. Characterization of monoclonal antibodies to equine interleukin-10 and detection of T regulatory 1 cells in horses.
Wagner B; Hillegas JM; Brinker DR; Horohov DW; Antczak DF
Vet Immunol Immunopathol; 2008 Mar; 122(1-2):57-64. PubMed ID: 18061278
[TBL] [Abstract][Full Text] [Related]
8. Cloning and functional characterization of recombinant equine P-selectin.
Xu J; Cai J; Anderson B; Wagner B; Albrecht R; Peek SF; Suresh M; Darien BJ
Vet Immunol Immunopathol; 2007 Apr; 116(3-4):115-30. PubMed ID: 17306378
[TBL] [Abstract][Full Text] [Related]
9. Targeting gamma interferon to tumor cells by a genetically engineered fusion protein secreted from myeloma cells.
Xiang J; Qi Y; Cook D; Moyana T
Hum Antibodies Hybridomas; 1996; 7(1):2-10. PubMed ID: 8886831
[TBL] [Abstract][Full Text] [Related]
10. Development of a bead-based multiplex assay for simultaneous quantification of cytokines in horses.
Wagner B; Freer H
Vet Immunol Immunopathol; 2009 Feb; 127(3-4):242-8. PubMed ID: 19027964
[TBL] [Abstract][Full Text] [Related]
11. Characterisation and quantification of equine interferon gamma.
Gutmann S; Zawatzky R; Müller M
Vet Immunol Immunopathol; 2005 Mar; 104(1-2):105-15. PubMed ID: 15661336
[TBL] [Abstract][Full Text] [Related]
12. Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins.
Xiang J
Hum Antibodies; 1999; 9(1):23-36. PubMed ID: 10331183
[TBL] [Abstract][Full Text] [Related]
13. Monoclonal anti-equine IgE antibodies with specificity for different epitopes on the immunoglobulin heavy chain of native IgE.
Wagner B; Radbruch A; Rohwer J; Leibold W
Vet Immunol Immunopathol; 2003 Mar; 92(1-2):45-60. PubMed ID: 12628763
[TBL] [Abstract][Full Text] [Related]
14. [Expression of human IL-35-IgG4 (Fc) fusion protein in CHO/DG44 cells].
Tang J; Gao W; Zhang Q; Zhang D; Chen Y; He B; Liu Q
Sheng Wu Gong Cheng Xue Bao; 2009 Jan; 25(1):109-15. PubMed ID: 19441235
[TBL] [Abstract][Full Text] [Related]
15. Intramuscular administration of expression plasmids encoding interferon-gamma receptor/IgG1 or IL-4/IgG1 chimeric proteins protects from autoimmunity.
Chang Y; Prud'homme GJ
J Gene Med; 1999; 1(6):415-23. PubMed ID: 10753067
[TBL] [Abstract][Full Text] [Related]
16. Expression and ligand binding assays of soluble cytokine receptor-immunoglobulin fusion proteins.
Brown SJ; Becherer KA; Blumeyer K; Kautzer C; Axelrod F; Le H; McConnell SJ; Whalley A; Spinella DG
Protein Expr Purif; 1998 Oct; 14(1):120-4. PubMed ID: 9758759
[TBL] [Abstract][Full Text] [Related]
17. Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors.
White DM; Jensen MA; Shi X; Qu Zx ; Arnason BG
Protein Expr Purif; 2001 Apr; 21(3):446-55. PubMed ID: 11281720
[TBL] [Abstract][Full Text] [Related]
18. Improving the efficacy of antibody-interleukin 2 fusion proteins by reducing their interaction with Fc receptors.
Gillies SD; Lan Y; Lo KM; Super M; Wesolowski J
Cancer Res; 1999 May; 59(9):2159-66. PubMed ID: 10232603
[TBL] [Abstract][Full Text] [Related]
19. Human IgG1 Cgamma1 domain is crucial for the bioactivity of the engineered anti-CD20 antibodies.
Geng S; Feng J; Li Y; Kang X; Sun Y; Gu X; Huang Y; Chang H; Shen BF
Cell Mol Immunol; 2007 Apr; 4(2):121-5. PubMed ID: 17484806
[TBL] [Abstract][Full Text] [Related]
20. Efficient expression of recombinant human monoclonal antibodies in Drosophila S2 cells.
Johansson DX; Drakenberg K; Hopmann KH; Schmidt A; Yari F; Hinkula J; Persson MA
J Immunol Methods; 2007 Jan; 318(1-2):37-46. PubMed ID: 17137589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
